Syndax Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
Syndax Pharmaceuticals, Inc. (SNDX) reported Capital Expenditures Incurred but Not yet Paid of $42.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2018-11-05
- Syndax Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-09-30 was $1.00K.
- Syndax Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2016-06-30 was -$22.00K.
- Syndax Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2016-03-31 was $73.00K.
- Syndax Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2015 was $27.00K, a 800.00% increase from fiscal 2014.
- Syndax Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2014 was $3.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2017-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $42.00K 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $41.00K 10-Q · filed 2018-08-08 | |||
| 2016-06-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $51.00K 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $73.00K 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $27.00K 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $3.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |